Publicaciones científicas

Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis

21-jul-2021 | Revista: Molecular Therapy Methods & Clinical Development

Sara Lumbreras 1 2, Ana Ricobaraza 1 2, Lucia Baila-Rueda 3, Manuela Gonzalez-Aparicio 1 2, Lucia Mora-Jimenez 1 2, Iker Uriarte 2 4 5, Maria Bunuales 1 2, Matias A Avila 2 4 5, Maria J Monte 5 6, Jose J G Marin 5 6, Ana Cenarro 3, Gloria Gonzalez-Aseguinolaza 1 2 7, Ruben Hernandez-Alcoceba 1 2


Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive disease caused by mutations in the CYP27A1 gene, encoding the sterol 27-hydroxylase.

Disruption of the bile acid biosynthesis pathway and accumulation of toxic precursors such as cholestanol cause chronic diarrhea, bilateral juvenile cataracts, tissue deposition of cholestanol and cholesterol (xanthomas), and progressive motor/neuropsychiatric alterations. We have evaluated the therapeutic potential of adeno-associated virus (AAV) vectors expressing CYP27A1 in a CTX mouse model.

We found that a vector equipped with a strong liver-specific promoter (albumin enhancer fused with the α1 anti-trypsin promoter) is well tolerated and shows therapeutic effect at relatively low doses (1.5 × 1012 viral genomes [vg]/kg), when less than 20% of hepatocytes overexpress the transgene.

This vector restored bile acid metabolism and normalized the concentration of most bile acids in plasma. By contrast, standard treatment (oral chenodeoxycholic acid [CDCA]), while reducing cholestanol, did not normalize bile acid composition in plasma and resulted in supra-physiological levels of CDCA and its derivatives.

At the transcriptional level, only the vector was able to avoid the induction of xenobiotic-induced pathways in mouse liver. In conclusion, the overexpression of CYP27A1 in a fraction of hepatocytes using AAV vectors is well tolerated and provides full metabolic restoration in Cyp27a1 -/- mice. These features make gene therapy a feasible option for the etiological treatment of CTX patients.

CITA DEL ARTÍCULO Mol Ther Methods Clin Dev. 2021 Jul 21:22:210-221. doi: 10.1016/j.omtm.2021.07.002. eCollection 2021 Sep 10.